Catherine Owen Adams, Acadia Pharmaceuticals CEO
November 6, 2024 07:04 AM EST
Pharma
FDA+

Aca­dia lands $150M sale of rare pe­di­atric PRV

Katherine Lewin

News Reporter

Aca­dia Phar­ma­ceu­ti­cals has sold its pri­or­i­ty re­view vouch­er for $150 mil­lion, the com­pa­ny said Tues­day, but did not dis­close the buy­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times